Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis
Wang, Xinting, Koehne-Voss, Stephan, Anumolu, Sree and Yu, Jing (2017) Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis. Journal of Pharmaceutical Sciences, 106 (11). pp. 3402-3409. ISSN 1520-6017
Abstract
Tobramycin inhalation solution given as a twice daily inhalation of nebulized aerosols of 300 mg is approved for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients over 6 years of age. To investigate tobramycin pharmacokinetics (PK) after inhalation of tobramycin in pediatric cystic fibrosis patients below 7 years, a population PK approach was used to evaluate tobramycin PK data in patients 6 months to 44 years of age from 4 clinical studies. The final model used a 2-compartmental, first-order absorption model with effect of body mass index on the apparent central volume of distribution. Relative bioavailability in patients between 6 months and 7 years increased with age by a linear relationship, and was modeled as a ratio to that of patients over 7 years. Simulation showed that steady-state concentrations of tobramycin are lower in pediatric patients 6 months to 6 years than those in patients over 6 years. However, systemic exposure is not predictive of clinical efficacy due to direct dosing at the infection site. P aeruginosa eradication rate and safety profile in patients less than 7 years of age were similar to patients older than 6 years; therefore, no dose adjustment is warranted in the younger pediatric patients.
Item Type: | Article |
---|---|
Keywords: | aerosol clinical pharmacokinetics pediatric population pharmacokinetics pulmonary delivery/absorption |
Date Deposited: | 22 Nov 2017 00:45 |
Last Modified: | 25 Jan 2019 00:45 |
URI: | https://oak.novartis.com/id/eprint/29798 |